Dr. Balar on IMvigor 210 Results for Metastatic Urothelial Carcinoma

Video

Arjun V. Balar, MD, assistant professor, Department of Medicine, co-leader of the Genitourinary Cancers Program, discusses updated results of cohort 1 of the IMvigor 210 study, which examined the efficacy of atezolizumab as first-line therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma.

Arjun V. Balar, MD, assistant professor, Department of Medicine, co-leader of the Genitourinary Cancers Program, discusses updated results of cohort 1 of the IMvigor 210 study, which examined the efficacy of atezolizumab (Tecentriq) as first-line therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma.

In the phase II study, 119 patients with metastatic urothelial carcinoma who were ineligible for standard cisplatin-based chemotherapy achieved a 24% reduction in tumor size and had a median survival of 14.8 months following treatment with atezolizumab.

During the trial, atezolizumab was administered at 1200 mg every 3 weeks until progression. The objective response rate was 24%; additionally, 75% of these responses are still ongoing. The complete response rate was 7%, while the partial response rate was 17%.

<<<

View more from the 2016 AUA Annual Meeting

Related Videos
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Sumanta Kumar Pal, MD, FASCO,
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
Kohei Shitara, MD
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Kian-Huat Lim, MD, PhD
Benjamin Garmezy, MD
Kathryn Beckermann, MD, PhD